Novel Nitrile Peptidomimetics for Treating COVID-19
- PMID: 35291756
- PMCID: PMC8848505
- DOI: 10.1021/acsmedchemlett.2c00030
Novel Nitrile Peptidomimetics for Treating COVID-19
Abstract
COVID-19 is a highly infectious disease caused by the viral pathogen SARS-CoV-2, causing an estimated 5.4 million fatalities globally in 2 years since its emergence in December 2019. On December 22, 2021, the U.S. FDA granted Emergency Use Authorization for the oral viral main protease inhibitor, Nirmatrelvir, to treat patients with mild-to-moderate COVID-19. This patent review reveals the structure-activity relationship of key inhibitors described in the patent WO 2021/250648 A1.
Published 2022 by American Chemical Society.
Conflict of interest statement
The author declares no competing financial interest.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
